Traditionally, the management of prostate cancer relies on prostate-specific antigen (PSA) level and imaging, such as prostate-specific membrane antigen positron emission tomography/computed tomography (PSMA PET/CT). This evidence concerns the gene FOLH1 and Familial prostate cancer.